Release Date: 20/12/13 10:02 Summary: First Supplementary Bidder's Statement Price Sensitive: Yes Download Document 292.04KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%